Efficacy and Safety of 500mg of Fulvestrant as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Lowell General Hospital
University of Colorado, Denver
University of Maryland Greenebaum Cancer Center
South Shore Hospital
Information provided by (Responsible Party):
Steven Come, MD, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
NCT00585507
First received: December 22, 2007
Last updated: January 15, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2014
  Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)